Long-term sufferers of insomnia who have not found lasting relief from such sleep aids as Ambien or Sonata should consider researching Rozerem, the only medication of its type approved in the treatment of sleeplessness.
Rozerem (ramelteon) is the first of a new class of insomnia drugs: melatonin receptor agonists. These are similar to the naturally-produced sleep [...]

[Read more →]

One of our favorite industry pundits is John Mack, author of Pharma Marketing News, Pharma Marketing Blog and The Pharma Blogosphere, and host of Pharma Marketing Talk. We recently asked him about his background, his readership and some current issues in pharma.
Cary: You started VirSci Pharma Marketing Network in 1997 and it has since [...]

[Read more →]

Takeda Pharmaceuticals North American, Inc. has been cited by the FDA for airing unapproved reminder ads for its sleep aid medication Rozerem. Here’s an excerpt from the citation letter, courtesy of PharmaLive:
While reminder ads are exempt from the requirement to disclose information relating to risks and effectiveness, for the reasons set forth below, we have [...]

[Read more →]